Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Apr;4(2):177-90.
doi: 10.3978/j.issn.2218-6751.2015.01.11.

The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention

Joanna Domagala-Kulawik  1
Affiliations
Review

The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention

Joanna Domagala-Kulawik. Transl Lung Cancer Res. 2015 Apr.

Abstract

Over a hundred years after the first description of this disease, lung cancer represents one of the major challenges in oncology. Radical treatment cannot be introduced in more than 70% of cases and overall survival rate does not exceed 15%. The immunosurveillance of lung cancer may be effective in early oncogenesis but is inhibited in the course of developing a clinically detectable tumor. Very low and heterogonous antigenicity of lung cancer cells leads to passive escape from anti-cancer immune defense. The cytotoxic lymphocytes (CTLs) that play a main role in the anticancer response are actively suppressed in the tumor environment and following regulatory mechanisms inhibit the recognition of tumor antigens by antigen presenting cells. The population of regulatory T cells (Tregs) is augmented and the expression of transcription factor-Foxp3 is markedly increased on tumor cells and tumor infiltrating lymphocytes (TIL). It is accomplished by M2 macrophage polarization, the activity of myeloid derived suppressor cells (MDSCs) and a significantly elevated concentration of cytokines: transforming growth factor beta (TGFβ) and IL-10 in the tumor microenvironment. Very active suppression of immune protection is the predominant role of the programmed death 1 (PD-1)-PD-L1 pathway. The blockage of this pathway was found to be an effective treatment approach; therefore the monoclonal antibodies are being intensively investigated in lung cancer patients. Cytotoxic T lymphocyte antigen-4 (CTLA-4) is the molecule capable of inhibiting the activation signal. The antibody anti-CTLA-4 improves CTLs function in solid tumors and lung cancer patients may benefit from use of this agent. The second way in lung cancer immunotherapy is production of anti-cancer vaccines using recognized cancer antigens: MAGE-A3, membrane associated glycoprotein (MUC-1), and EGF. It was recently shown in ongoing clinical trials that combined therapies: immune- and chemotherapy, radiotherapy or targeted therapy seem to be effective. Immunotherapy in lung cancer has an individual character-there is a need to assess the patient's immune status prior to implementation of immunomodulating therapy.

Keywords: Lung cancer; cytotoxic cells; immune response; immunotherapy; regulation; vaccines.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Dendritic cell as an antigen presenting cell triggers priming of tumor specific T cells co-stimulatory pathways. APC, antigen presenting cell; NK, natural killer cell.
Figure 2
Figure 2
The essentials of tumor cells interaction with immune system. APC, antigen presenting cell; NK, natural killer cell.
Figure 3
Figure 3
Role of transforming growth factor beta (TGFβ) in lung cancer progression. CTLs, cytotoxic lymphocytes; Foxp3, forkhead box P3.
Figure 4
Figure 4
Trends of non-small cell lung cancer (NSCLC) immunotherapy in light of the current knowledge. CTLs, cytotoxic lymphocytes.
See this image and copyright information in PMC

References

    1. Adler IA. Classics in oncology: Primary malignant growths of the lung. CA Cancer J Clin 1980;30:295-301. - PubMed
    1. Alberg AJ, Brock MV, Ford JG, et al. Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143:e1S-29S. - PMC - PubMed
    1. European Respiratory Society. eds. European Lung White Book. Washington, DC: European Respiratory Society, 2014.
    1. Howington JA, Blum MG, Chang AC, et al. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143:e278S-313S. - PubMed
    1. Thunnissen E, van der Oord K, den Bakker M.Prognostic and predictive biomarkers in lung cancer. A review. Virchows Arch 2014;464:347-58. - PubMed